Penumbra
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 560m | 748m | 847m | 1.1b | 1.2b | 1.4b | 1.6b |
| % growth | 2 % | 33 % | 13 % | 25 % | 12 % | 15 % | 14 % |
| EBITDA | (38.9m) | (7.5m) | 6.1m | 127m | 148m | 222m | 279m |
| % EBITDA margin | (7 %) | (1 %) | 1 % | 12 % | 12 % | 16 % | 18 % |
| Profit | (15.7m) | 5.3m | (2.0m) | 91.0m | 30.7m | 141m | 191m |
| % profit margin | (3 %) | 1 % | - | 9 % | 3 % | 10 % | 12 % |
| EV / revenue | 11.3x | 14.4x | 9.8x | 9.0x | 6.3x | 5.5x | 4.6x |
| EV / EBITDA | -163.2x | -1431.0x | 1362.5x | 75.4x | 51.0x | 33.5x | 25.9x |
| R&D budget | 90.0m | 105m | 79.4m | 84.4m | - | - | - |
| R&D % of revenue | 16 % | 14 % | 9 % | 8 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | $120k | Seed | |
| N/A | $125m Valuation: $1.2b | IPO | |
| Total Funding | AUD185k | ||
Related Content
Recent News about Penumbra
EditPenumbra Inc. is a healthcare technology company specializing in innovative medical devices designed to treat neurovascular and peripheral vascular conditions. The company operates in the medical device market, focusing on providing advanced solutions for healthcare professionals, particularly those working in neurology and vascular surgery. Penumbra's primary clients are hospitals, clinics, and medical professionals across Europe and the Americas, including countries like Germany, Italy, the Netherlands, Poland, Portugal, Switzerland, the United Kingdom, and the United States.
Penumbra's product portfolio includes a range of neuro and peripheral devices. For neuro interventions, they offer the Penumbra System, ACE Family, 3D Revascularization Device, MAX Family, Velocity, Penumbra SMART COIL, Penumbra Coil 400, Neuron System, BENCHMARK 071, Penumbra Select Catheters, PX SLIM, and the Artemis Neuro Evacuation Device. These devices are designed to treat conditions such as stroke and other neurovascular diseases. In the peripheral segment, Penumbra provides the Indigo System, Indigo System Catheters, Indigo System Separators, Ruby Coil, POD System, and LANTERN, which are used to address peripheral vascular diseases.
Penumbra's business model revolves around the development, manufacturing, and distribution of these specialized medical devices. The company generates revenue by selling these devices to healthcare institutions and professionals. Additionally, Penumbra invests in continuous research and development to innovate and improve its product offerings, ensuring they meet the evolving needs of the medical community.
In summary, Penumbra Inc. is a key player in the medical device industry, providing cutting-edge solutions for neurovascular and peripheral vascular conditions. The company serves a global market, focusing on delivering high-quality, effective medical devices to healthcare professionals.
Keywords: Neurovascular, Peripheral Vascular, Medical Devices, Healthcare, Innovation, Stroke Treatment, Vascular Surgery, Hospitals, Clinics, Research and Development.